Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Collaborative Groups / Prostate and Urologic Cancers Research Group / Completed validation of %[-2]proPSA to improve PSA-based detection of prostate cancer; IVD FDA approved

Completed validation of %[-2]proPSA to improve PSA-based detection of prostate cancer; IVD FDA approved

Click here to view more information in the biomarker database for proPSA

Announcement 10/27/2016

Thank you to everyone who contributed to the successful and productive EDRN Orientation Meeting in October. The next EDRN Steering Committee Meeting will take place in March 6-9, 2017 in Tempe, AZ. More information about this meeting will be available soon.

Announcement